Dermapharm Holding SE Capital Expenditures (CapEx) Growth & History (DMP)
Dermapharm Holding SE's capital expenditures (capex) was €42.1M for fiscal 2025.
View full Dermapharm Holding SE company overviewDermapharm Holding SE annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €42.1M | €3.9M | +10.15% |
| 2024 | 2024-12-31 | €38.2M | −€3.3M | −7.95% |
| 2023 | 2023-12-31 | €41.5M | €2.5M | +6.48% |
| 2022 | 2022-12-31 | €39.0M | −€22.2M | −36.25% |
| 2021 | 2021-12-31 | €61.2M | — | — |
Dermapharm Holding SE quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | €14.9M | €4.5M | +43.09% |
| Q1 2026 | 2026-03-31 | €11.8M | €1.8M | +17.58% |
| Q4 2025 | 2025-12-31 | €11.9M | — | — |
| Q3 2025 | 2025-09-30 | €9.7M | — | — |
| Q2 2025 | 2025-06-30 | €10.4M | — | — |
| Q1 2025 | 2025-03-31 | €10.1M | — | — |
Dermapharm Holding SE capital expenditures (capex) trends
Between the periods ended 2021-12-31 and 2025-12-31, Dermapharm Holding SE's capital expenditures (capex) decreased from €61.2M to €42.1M, a change of −€19.1M. The latest reported quarter, Q2 2026, shows €14.9M.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company official filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Dermapharm Holding SE source filings ↗